News Hub | News Direct

NEW STUDY SHOWS NOVEL PERSONALIZED SYSTEMS NUTRITION PROGRAM IMPROVES DIETARY PATTERNS, LIFESTYLE BEHAVIORS AND HEALTH-RELATED OUTCOMES

Nlumn

The Habit PATH (Personalized Approaches To Health) Study demonstrates that a Personalized Systems Nutrition program in a workforce environment improves dietary habits, health markers, physical activity and other health-related outcomes. The Habit PATH Study helps validate a holistic approach to personal nutrition that: Introduces a new approach that customizes nutrition systems according to an individual’s phenotypic flexibility assessment, which measures health according to their ability to adapt to a temporary nutritional stressor or an environmental challenge. This technology can identify potential health concerns to allow for early intervention and treatment. Provides personal goal setting and motivational interviewing to affect behavioral change and improve an individual’s adherence to lifestyle intervention programs. The Habit PATH Study suggests that personalized nutrition programs may provide the tools and motivation to enable individuals to meet their unique needs, achieve public health recommendations and improve health-related outcomes that may help reduce the health economic burden of chronic disease. Nlumn, LLC, a personalized nutrition and health company, announced health outcomes from a study of a novel Personalized Systems Nutrition program in the June 2021 issue of Nutrients. The peer-reviewed Habit PATH Study is the first to incorporate phenotypic flexibility technology in Personalized Systems Nutrition programs to improve the dietary patterns, lifestyle behaviors and health-related outcomes of individuals in a workplace environment. “The Habit PATH Study shows that personalized science-based nutrition and behavior interventions have the potential to improve overall diet quality and health markers that could reduce the chronic disease burden and improve the overall state of health in the United States,” said Josh Anthony, Ph.D., Founder and CEO, Nlumn and co-author of the study. “The results suggest that a systems-based personalized nutrition approach, combining both biological and behavioral science, not only helps address an individual’s unique health needs, but also helps them achieve public health recommendations, including the Dietary Guidelines for Americans. Consequently, personalized approaches may be more effective in motivating people to achieve public health recommendations compared to general guidelines.” Participants saw health changes that were consistent with public health recommendations including: Saturated fat intake was reduced more than 20%. Total sugar and sodium intake were reduced by almost 20%. These changes are consistent with the 2020-2025 Dietary Guidelines Key Recommendations to limit specific nutrients. Key nutrients such as potassium, fiber, magnesium, vitamin C and beta carotene increased, suggesting increased intake of fruit and vegetables. While this was not designed to be a weight loss study, caloric intake decreased 13% and participants saw reduced body weight, BMI, hip circumference and a reduction in body fat. Physical activity also increased. The most unhealthy participants reported a 10% reduction in total cholesterol and a 15% decrease in LDL (bad) cholesterol. “This study shows that assessing health status by using phenotypic flexibility to direct personal nutrition recommendations enables positive lifestyle changes and health outcomes regardless of an individual’s level of health,” according to Iris M. de Hoogh, scientist, Netherlands Organization for Applied Scientific Research (TNO) and lead author of the study. “The application of TNO’s Phenotypic Flexibility Technology helps identify early health interventions that individuals can address with their healthcare professionals before the health concern becomes a significant issue.” Anthony continued, “At a time when the U.S. is facing a multidimensional, multigenerational health crisis, and consumer demand for more nutritious food is at an all-time high, this study also helps verify the ability to use personalized subcategories to tailor food and product innovation pipelines in a meaningful way – thereby increasing the potential for long-term positive health benefits from personalized nutrition for food and insurance companies.” As part of this study, Personalized Systems Nutrition algorithms provided the employer’s food service partner with recommendations used to tailor breakfast and lunch options to align with study participants’ individual health needs. HABIT Study Results: Results of the study show that personalized nutrition programs are more effective for improving diet quality, supporting improved health-outcomes and may enable healthier lifestyle behaviors, particularly among individuals who have compromised phenotypic flexibility, a measure of the body’s ability to adapt to nutritional or environmental stressors, such as physical exercise, infections or mental stress. During the HABIT Study 10-week personalized intervention, participants showed statistically significant results: Dietary Indicators: Notable dietary improvements were observed between the intervention. Including a decrease in total and saturated fat, sugar and sodium, while showing improvements in vitamin C, magnesium, potassium, and beta carotene intake, suggesting a higher intake of fruits and vegetables. Notes: 73 participants were included in the per protocol analysis. Health Indicators: During the intervention, participants received personalized dietary recommendations, coaching and personalized meals. Several health improvements were observed for the overall study population. While this was not designed to be a weight loss trial, BMI (-0.6 kg/m2; p<0.0001), body fat (-1.2%, p=0.0192) and hip circumference (-5.8 cm; p<0.0001) showed a significant decrease. Subgroup Results: In reporting health measurements, the Habit Study’s automated Personalized Systems Nutrition algorithms assigned individuals to different subgroups based on their metabolic health status determined by phenotypic flexibility assessment at baseline. Groups A (n=48) and G (n=22) represented the most and least phenotypically flexible groups, respectively. Group G had a higher degree of adiposity, and a higher age than group A. However, there were no differences in baseline dietary intake and both groups were 82% compliant with personalized meal intake. Clinical Chemistry (fasting): For group G, significant reductions in total cholesterol and LDL (“bad”) cholesterol were seen during the intervention. There were 48 and 22 subjects in groups A and G, respectively. *p<0.01, **p<0.0001 Subgroup differences during the 10-week intervention. Anthropometrics: During the intervention period, body weight significantly decreased in both group A (most healthy) and group G (least healthy). Notes: At baseline, BMI, body weight, body fat, waist circumference and hip circumference were greater in group G compared to group A. Percentages were used to normalize differences between groups, but absolute changes were proportionately greater in group G given higher starting values. Statistically significant differences are noted in the last two columns for changes in the groups A or G respectively and in the first column for changes in the per protocol study population; (*p<0.05; **p<0.001; ****p<0.0001). Subgroup population size may have limited the ability to detect differences in some measures that were observed in the overall study (per protocol) population. Dietary Indicators: When looking at subgroups A and G, the Personalized Systems Nutrition program not only improved adherence with population-based dietary guidelines, but also achieved better alignment with individual recommendations. For the unhealthiest group, G, different positive effects were seen with respect to dietary intake, consistent with their respective dietary recommendations. Protein and beta carotene intake increased in group G, but not in group A. The increase in protein intake can be directly related to the personalized advice for group G as they were recommended to consume a diet higher in protein relative to group A. The increase in beta carotene could be the result of a higher intake of fruits and vegetables. The results suggest that personalized nutrition programs may be more effective in motivating people to consume a diet that meets individual needs while moving them closer to public health recommendations overall. As such, personalized nutrition programs have added value as compared to general guidelines or one-size fits all recommendations. Physical Activity: The intervention resulted in an increase in physical activity within the study participants of more than 700 steps per day. This was accompanied by a small decrease in resting heart rate which could indicate improved physical fitness. This increase is interesting, since the intervention consisted only of dietary advice and participants did not receive recommendations on physical exercise. The increase in physical activity may be a beneficial side-effect of participating in a Personalized Systems Nutrition program. HABIT Study Trial Design The Habit Study enrolled 107 healthy men and women, aged 30 to 65 years of age, with a body mass index between 18.5 to 39.9 kg/m2, and who were recruited from a single workforce location. The intervention grouped individuals into seven diet types and created personalized recommendations based on their phenotypic, genotypic and behavioral data. The HABIT study was a single-arm, multi-phased, open-label exploratory trial designed to measure the effectiveness of personalized nutrition on changing lifestyle behaviors and health outcomes during four intervention periods. These four periods were classified as: Baseline (week 0) and run-in (week 0 - 10) Intervention Phase 1 (week 10 - 20) Intervention Phase 2 personalized coaching/advice (week 20 - 30) Follow-up (week 30 - 40) endpoint visit only. The publication focuses on the baseline through intervention Phase 1. As part of the study, participants received: An At-Home Phenotypic Flexibility Test and Sample Collection for collecting buccal cells, a series of three dried blood spots (DBS) and DNA (baseline only) samples. A Personalized Systems Nutrition Program designed by using individual on-boarding data, clinical measures and single nucleotide polymorphism (SNP) variants. Micronutrient recommendations were determined using onboarding, anthropometric and clinical measures. In addition, participants were provided with personalized recipes and meals according to their macro- and micronutrient recommendations. Three personalized coaching sessions by registered dietitian nutritionists (RDN) who were trained on coaching techniques and the algorithms supporting the Personalized Systems Nutrition system. These RDNs provided food and diet recommendations, helped motivated participants and coached them in setting and achieving personal goals. Study meals and compliance diaries. Starting at week 10, participants received tailored breakfast and lunch five days a week for nine weeks. Activity measurement. At the start of the trial, each participant was given a Fitbit® to measure and record their activity level. Approximately every five weeks participants would visit the study center to be tested and have data collected on: Clinical markers: Regular laboratory tests were conducted to track total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, C-peptide, and the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and Matsuda indices measuring whole body insulin sensitivity. Dietary Intake: Using a standard dietary record methodology, participants tracked their food and beverages consumed for three days (two weekdays and one weekend day) prior to all visits. Anthropometrics and Vitals: During each visit, anthropometrics--height (first visit only), weight, fat mass, waist and hip circumference--and blood pressure were measured. Wellbeing and Lifestyle: Participants’ dietary behavior was assessed using the 34-item Adult Eating Behaviors Questionnaire and their Quality of Life using the 26-item World Health Organization Quality of Life (WHOQOL) questionnaire. Their daily activity and sleep were tracked with a Fitbit Charge 2 which monitored heart rate, number of steps and sleeping hours. About Personalized Systems Nutrition Personalized Nutrition is the use of individual-specific information, founded in evidence-based science, to promote dietary behavior change that may result in measurable health benefits. Personalized Systems Nutrition incorporates novel Phenotypic Flexibility Technology that customizes diets according to an individual’s phenotypic flexibility allowing them to measure their health according to their biological system’s ability to adapt to conditions of temporary stressors, such as a nutrition challenge, physical exercise, infections or mental stress. This technology helps identify potential early health interventions that individuals can address with their healthcare professionals before it becomes a significant health issue. By combining systems-based approaches to understanding a person’s biology and behavior science, Personalized Systems Nutrition programs are able to create significant and sustainable changes in a person’s health and wellness. About Nlumn Nlumn works with food, nutrition and health-based companies to translate nutrition science and technology to create new opportunities across the personalized nutrition marketplace. Our international, multidisciplinary team guides partners through all phases of strategy and development to accelerate the pace of innovation, from discovery to commercialization. Our mission is to make personalized nutrition accessible to help every individual make better choices and live a healthier life. For more information, visit www.nlumn.com. About TNO TNO (Netherlands Organization for Applied Scientific Research) is a not-for-profit research organization with the mission to connect people and knowledge to create innovations that boost the competitive strength of industry and the well-being of society in a sustainable way. TNO’s Healthy Living unit develops social and technological innovations to help people lead healthier lives and reduce lifestyle-related chronic diseases. TNO developed the phenotypic flexibility technology that was instrumental in the Habit PATH study. For more information, visit https://www.tno.nl/en/focus-areas/healthy-living/. Contact Details AgTech PR for Nlumn Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com

July 21, 2021 09:00 AM Eastern Daylight Time

Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan

Kadimastem LTD

Cell therapy company Kadimastem Ltd ( TASE: KDST ) has received its patent approval from the Japanese Patent Office for IsletRx, the company’s innovative treatment for diabetes. IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when blood sugar is low and glucagon, a hormone secreted to prevent hypoglycemia, when blood sugar levels drop in response to varying sugar levels (glucose) in the blood. This particular function of IsletRX is similar to a "healthy" pancreas and functions to treat insulin-dependent diabetes, such as Type 1 diabetes also known as juvenile diabetes. The patent announced today protects Kadimastem’s cell selection and enrichment technology, that enables it to identify and fortify the best cells in the expanded population. The patent also covers the use of the company’s special production process, where it can remove cells that are not necessary or may impair the efficiency of the transplanted cells. These capabilities are important in achieving the maximum therapeutic effect for potential future insulin-dependent diabetic patients. In addition, this method of production and cell selection enables the ILCs to be transplanted using a variety of platforms, including very small devices that are more suitable and more convenient for patients. Kadimastem CEO Asaf Shiloni said, “Receiving the patent in Japan further strengthens our intellectual property position. The market, in Southeast Asia in general, and the Japanese market, are large and important for the company's future products. Registering the patent in Japan gives Kadimastem a much-welcomed priority status in this territory. We look forward to further developing business collaborations with key players in the pharmaceutical industry in Japan, both for our diabetes and ALS products.” The Japanese market is one of the most significant markets for stem cell-derived cell therapies. In Japan, 7.9% of the population is diabetic and there are more than 2.7 million insulin-dependent diabetic patients. Treatment of these patients is currently estimated at $ 29 billion. Japan has strategic importance in the field of stem cell therapy, as it is one of the world's most prominent countries in promoting innovation and products in the field of cell therapy. In November 2014, the Japanese Parliament approved a special law to facilitate clinical trials in the field of cellular medicine, with the aim of expediting approvals of intracellular therapies and quickly bringing them to market. Social Media: LinkedIn, Twitter, Facebook Company Contacts: Asaf Shiloni CEO a.shiloni@kadimastem.com Press Contact: Marjie Hadad General Manager Must Have Communications 917-790-1178 marjie@mhc-pr.com About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. Kadimastem is focusing on two promising products, AstroRxÂ® and IsletRX. AstroRxÂ®, the Company's clinically advanced product, is an astrocyte cell therapy in clinical development as a treatment for ALS and other neurodegenerative diseases. IsletRx, is comprised of functional Stem Cell derived pancreatic islet cells intended to cure patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in preclinical studies. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of RebifÂ®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 â 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Asaf Shiloni +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

July 21, 2021 09:00 AM Eastern Daylight Time

R2 Technologies Receives Series C Investment to Fuel Business Growth, Expand Corporate Footprint and Tap into the Global Market

R2 Technologies

R2 Technologies Inc. ("R2") has received an additional round of $15 million in funding from its founding investor, Pansend Life Sciences, LLC, as a Series C equity investment which closed on July 20, 2021. The investment established a post-money valuation of $150 million for R2. The funds will be used to expand the company’s corporate footprint and US commercial acceleration of Glacial Rx™, its first-to-market revolutionary CryoAesthetic™ treatment, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation. The investment will also fuel global growth and development of R2 Technologies’ upcoming innovations that are currently planned for future rollout. “It is exciting to see our founding investor, Pansend, reinvest in the company. It is a testament to our business and the growth trajectory within the US and global markets,” says Tim Holt, R2’s Chief Executive Officer. “In fact, we will be one of the first global players in aesthetics who will have an East Coast office in Miami, Florida. This expansion will give us an unprecedented advantage especially as we expand globally and mobilize our growing sales force.” In preparation for the unprecedented growth expected in the upcoming year, R2 is accelerating its manufacturing process to meet the current pent-up and future anticipated demands from the professional market. Additionally, the team will be ramping up marketing efforts to further drive education and awareness across both the consumer and professional channels. R2 is doubling down on its presence in Silicon Valley with the expansion of its main office, while establishing a Miami-based satellite office. According to a recent article, Florida has been noted as one of the hottest new business hubs with Fortune 500 businesses and tech firms expanding into the flourishing market, leading to notable financial growth. Furthermore, RealSelf named Miami at the top of its list for the most aesthetic treatment providers and plastic surgeons per capita in 2018 and noted a strong correlation between tech hub hotspots and top medaesthetic markets, making it a prime marketplace for R2’s in-office treatments. Developed by the pioneers of CoolSculpting and Fraxel, Glacial Rx was named among ‘2021 Launches Doctors are Buzzing About’ according to RealSelf, the leading and most trusted source to educate on cosmetic procedures. Most recently, R2 was named winner of the 2 nd Annual Aesthetics Tech Summit LaunchPad SBDC, hosted by Octane, a company committed to making resources, capital and mentorship available to tech and medtech startups. R2 is actively taking orders from aesthetic providers who want to offer the new Glacial Rx treatment in-office. To learn more about R2 Technologies, treatment offerings and providers, visit glacialskin.com and follow the company on LinkedIn. About R2 Technologies: Headquartered in Silicon Valley, R2 Technologies is a world leader in CryoAesthetic™ medical devices. In 2014, Pansend Life Sciences, LLC and Blossom Innovations, LLC founded R2 Technologies and licensed exclusive intellectual property from Massachusetts General Hospital. In 2019, R2 brought on strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand’s scientiﬁc founders and world-famous luminaries in aesthetic medicine, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Since inception, R2 has raised $76 million in ﬁnancing led by a world-class team of experts within the aesthetics industry. Contact Details Linsey Tilbor Rubin +1 732-991-5294 ltilbor@rellmc.com Company Website https://glacialskin.com/

July 21, 2021 08:00 AM Eastern Daylight Time

American Kidney Fund Supports Emerging Researchers Through Two New Clinical Scientist in Nephrology Fellowship Awards

American Kidney Fund

The American Kidney Fund (AKF) today announced the newest recipients of research funding from its Clinical Scientist in Nephrology Program, which has been funding the most promising emerging clinical researchers in nephrology for over 30 years. Christine Limonte, MD, a nephrology clinical research fellow at the University of Washington, and Elizabeth Kermgard, MD, a pediatric nephrology fellow at Children’s Hospital Los Angeles (CHLA), have been awarded two-year AKF research fellowships which began July 1. Dr. Limonte and Dr. Kermgard join a distinguished roster of more than 40 top nephrology researchers who received early-career support from AKF through the Clinical Scientist in Nephrology Program. AKF’s program strives to improve the quality of care provided to kidney patients. Since 1989, AKF has funded researchers whose work is designed to improve diagnosis, treatment and outcomes for patients living with chronic kidney disease (CKD) and kidney failure. The fellowships announced today are funded by generous grants from Akebia Therapeutics, Kissinger Family Foundation, John and Maria Laffin Trust and an anonymous donation from a family foundation. “We are proud to award our newest AKF Clinical Scientist in Nephrology fellowships to two impressive women who are paving the way to advance clinical research and have a lasting impact on people with kidney disease,” said LaVarne A. Burton, AKF President and CEO. “We are grateful for the support of our funders for their generosity in helping to fund this important research program, which has made invaluable contributions to our understanding of kidney disease and improvements in patient care for more than 30 years.” Dr. Limonte’s research is utilizing novel analytics techniques to determine if blood vessel disease in the back of the eye, or retinopathy, can reveal information about kidney function and kidney disease. The goal of the investigation is to better diagnose and treat diabetic kidney disease. In a two-part study, Dr. Limonte will first use machine learning on medical record data from 10,000 patients to look at associations between kidney function and eye disease. In the second part, she will work with the Kidney Precision Medicine Project to analyze kidney biopsy samples from 75 people, using genetic data to help decipher mechanisms of kidney disease. “Diabetes is one of the leading causes of kidney failure in the U.S., and it disproportionately impacts people from lower socioeconomic backgrounds. I want to get a better understanding of the biology of diabetic kidney disease, so that we can deliver better care to a group that desperately needs it,” said Dr. Limonte. “My research will begin the discovery process to determine the molecular pathways that link retinopathy and diabetic kidney disease. This will hopefully help with diagnosis, and ultimately, lead to the discovery of treatments that might work better in some patients.” Dr. Kermgard is studying the relationship between gut microbiome and CKD, and how the interactions of bacteria in our body may impact normal bone growth and turnover—the process of resorption followed by replacement of new bone with little change in shape that occurs throughout a person's life. Her research will enroll 48 pediatric dialysis patients between the ages of six and 21, who have not been on immunosuppressive drugs or growth hormones in the last four weeks and have normal bone turnover. Her team will collect blood and stool samples and utilize shotgun sequencing to look at the microbiome, conduct analysis of short-chain fatty acids and capture the levels of parathyroid hormone (PTH) fragments, an important indicator of mineral and bone disease in CKD patients. “When you work in pediatric nephrology, you see children who are suffering from bone disease every day,” said Dr. Kermgard. “When these young patients with bone deformities are in front of you and you know that mineral and bone disease can lead to increased cardiovascular risk, it’s hard not to intervene. I hope my research one day leads to the finding of an intervention that can change the microbiome or SCFA production and improve bone growth in these pediatric patients.” Dr. Limonte graduated magna cum laude from Brown University and received her medical degree from University of Pennsylvania. She completed her internal medicine residency at Northwestern University. Now, as a Nephrology Clinical Research Fellow at the University of Washington, she is working with the Kidney Precision Medicine Project, a national, NIH-sponsored consortium established to develop a better understanding of the molecular pathways involved in kidney disease. The fellowship will support her work in bringing together biology with patient-centered care. Dr. Kermgard completed her Bachelor of Science degree in Molecular, Cell and Developmental Biology at the University of California, Los Angeles (UCLA) and received her Doctor of Medicine degree from Saint Louis University. After medical school, she completed her pediatric internship and residency at CHLA, where she is currently completing her first year of fellowship in pediatric nephrology. In parallel with her research, Dr. Kermgard will pursue a Master of Science in Clinical, Biomedical and Translational Investigations degree at the University of Southern California (USC). About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck 11921 Rockville Pike, Suite 300 Rockville, MD 20852 AKF@jpa.com Company Website http://www.kidneyfund.org/

July 19, 2021 09:00 AM Eastern Daylight Time

No Dogs Left Behind Now Sells Organic CBD Oils and Treats To Support Its Dog Meat Trade Survivors Rescued From Slaughterhouses, Dog Meat Trucks

No Dogs Left Behind

No Dogs Left Behind, a global animal welfare organization, now sells organic CBD oils and treats specifically designed for your dog. NDLB is offering these new products through a strategic alliance with Pawse, a company founded by four best friends with backgrounds in agriculture, hemp farming, thoroughbred training, business and engineering. Pawse plants, grows, harvests and extracts the CBD for its pet products all on its farm in Paris, Kentucky. “We were looking for a product that would be helpful for our survivors of the illegal dog meat trafficking trade in East Asia” says Jeffrey Beri, Founder and President of No Dogs Left Behind. “Product quality is paramount in an industry that lacks regulation and oversight. We decided to enter into this strategic alliance with Pawse because they meticulously control every step in the process, ensuring only the highest quality products are used. Perhaps most notable to us is they validate their products with ISO accredited third party lab results, which was something critical to us when deciding to enter into this alliance.” “It’s incredible how effective these all-natural products can be in helping calm and relax dogs and often improve their overall quality of life, especially as they age,” said Bradley Kerrick, a partner at Pawse, founded in 2019. Kerrick explains “there are studies that indicate that CBD may enhance immune system function, promote relaxation and calming, and helps maintain joint mobility. In essence, said Kerrick, “CBD from hemp is used to supplement a dogs existing endocannabinoid system, and leads to better cellular communication within their bodies, ideally, helping promote homeostasis and optimal function.” In addition to daily use for helping promote overall health and wellness, Kerrick notes many people find uses for these products during specific scenarios such as peak fireworks times, thunderstorms, road trips or visits to the vet, and for large crowds where dogs can quickly become overwhelmed. “We have seen that a lot of people have found use for CBD products for their dogs when they head back to the office and their pup is at home wondering why mom and dad are gone so much these days.” CBD treatment is especially helpful to dogs rescued from the dog meat trafficking trade, many of whom have experienced extreme stress and trauma. “There are so many things that trigger them because that’s what they went through,” he said, such as noises from lawnmowers, buses, snow blowers, motorcycles and vacuum cleaners. CBD products, notes Beri, can help your dogs “embrace the environment versus react in a fearful way.” These freeze-dried CBD treats and oil are available for purchase at http://www.nodogsleftbehind.com. NDBL is working with Pawse on additional products such as plant-based CBD treats and gravies. “We are excited to offer these products to our adopters and other pet lovers whose dogs can benefit from CBD on a daily basis and for additional help during stressful situations for their in dogs” says Beri. About No Dogs Left Behind: No Dogs Left Behind operates boots on ground in East Asia, fighting on the frontlines to rescue dogs from the illegal dog meat trafficking trade. We work hands-on with local activists through emergency response, pulling dogs directly from slaughterhouses, dog meat trucks, wet markets and traffickers. Our mission extends beyond borders, advocating for the creation and enforcement of animal welfare laws and raising awareness for a cruelty-free, sustainable world in which no animal is violated, exploited, tortured or slaughtered for commercial goods or profit. With nearly 500 survivors in our care, No Dogs Left Behind operates sanctuaries in Dayi and Gongyi, China. Follow us on Facebook, Instagram, YouTube, Twitter, TikTok and Pinterest. Contact Details No Dogs Left Behind Sherry Chen +1 855-665-0888 sherry@nodogsleftbehind.com Company Website http://www.nodogsleftbehind.com

July 19, 2021 08:00 AM Eastern Daylight Time

Image

Amazon and Microsoft Veterans Join Forces with the Allen Institute for A.I. to Launch MajorBoost

MajorBoost

Three tech and healthcare veterans collaborating at the Allen Institute for AI (AI2) today launched MajorBoost. The AI-based communication and decision support company is set to significantly improve efficiency in the healthcare system by reimagining how doctor’s offices and insurance companies communicate with each other. “Instead of spending more time on patient conversations and conducting health care follow-ups, medical providers are spending endless hours on the phone navigating the maze of health insurance call centers,” said Lekshmi Venu, co-founder and CEO of MajorBoost. “MajorBoost empowers providers to get their questions answered quickly, resolve insurance issues faster, and ultimately grow their patient service and human connection.” It’s estimated that medical providers lose $35B annually due to antiquated processes and inefficiencies in the insurance system, simply because they’re trying to confirm patient eligibility, claim status, and other administrative tasks. By serving the more than 2M medical billers, front desk staff and call center staff in the healthcare industry, MajorBoost has the potential to change lives and the nature of work. “The pain is real, and the younger generations aren’t going to put up with the current system,” said Ben Hesketh, co-founder and CTO of MajorBoost. “Our AI-enabled phone automation delivers productivity, intelligence and decision support to healthcare teams, getting them off the phone and back to helping patients.” With general availability imminent, MajorBoost is already working with private practices that report seeing immediate results including a boost in same-day issue resolution rates and more patient conversations by using the AI-based tool. Healthcare providers can register for access to MajorBoost at www.majorboost.com. About MajorBoost MajorBoost is founded by technologists who personally live with the challenges of health insurance reimbursement, and were leaders at major tech companies and health plans. Backed by the Allen Institute for AI, MajorBoost builds cutting edge AI to improve the lives of patients, healthcare workers, and call center agents. About the MajorBoost Founders As CEO of MajorBoost, Lekshmi Venu is building on her experiences at both Amazon and the healthcare industry. Prior to co-founding MajorBoost, Lekshmi led a global data science and AI team at Amazon. After earning her MBA at Harvard Business School, Lekshmi held leadership roles at Express Scripts (Cigna) and a mid-size long-term care distributor. Ben Hesketh, CTO of MajorBoost, is a tech innovator and entrepreneur. Ben created first generation products in IoT, AR/VR and NLP and amassed over fifteen patents to date with Microsoft. He began his software career in video game development soon after graduating from Cambridge with dual degrees. MajorBoost is Ben’s third co-founded startup. Andrew Palmer, VP of Engineering, is a technologist and professional weightlifter with a passion for improving the lives of patients and healthcare providers. After graduating with an Engineering degree from University of Dayton, Andrew developed health insurance software and later joined Microsoft as a software developer. Andrew was a developer at Moz and Rover, and most recently founded and led engineering for a social network with over 500K users. About the Allen Institute for AI (AI2) AI2 was founded in 2014 with the singular focus of conducting high-impact research and engineering in the field of artificial intelligence, all for the common good. AI2 is the creation of Paul Allen, Microsoft co-founder, and is led by Dr. Oren Etzioni, a leading researcher in the field of AI. AI2 employs more than 200 top researchers and engineers from across the globe. To date, AI2 has spun out over 10+ companies via its commercialization arm, the AI2 Incubator. Learn more at allenai.org and ai2incubator.com. Contact Details Owen Media Forrest Carman +1 206-859-3118 forrestc@owenmedia.com Company Website https://www.majorboost.com/

July 15, 2021 07:03 PM Eastern Daylight Time

Modulus Therapeutics Secures Funding for Cell Therapy Design Platform, Adds Alana Welm and Raphael Gottardo to Advisory Board

Modulus

Modulus Therapeutics, an artificial-intelligence powered cell therapy design company, announced it completed an oversubscribed $3.5 million Seed round. The round was led by Madrona Venture Group, with participation from KdT Ventures, and the Allen Institute for AI (AI2). Modulus also announced the formation of their Scientific Advisory Board with founding members Alana Welm and Raphael Gottardo. The new funding will be used to expand development of Modulus' Convergent Design™ platform that combines key technology components, including gene editing, machine learning, multi-omics, and high-throughput in vivo screening to bring an intelligent, unbiased approach to immune cell therapy design. “Modulus has an ambitious goal and an innovative platform combining modern machine learning, synthetic biology, and cutting-edge lab automation to treat tumors and eradicate cancer,” said Chris Picardo, Investor at Madrona Venture Group. “Their method unlocks true high throughput screening for cancer-fighting immune cells and creates a massive new dataset that is perfectly suited for AI. We are excited to work with them as they build out their team and capabilities.” Modulus is first focused on developing therapies based on natural killer (NK) cells for the treatment of metastatic breast cancer, building on recent momentum in deploying these cells against solid tumors. Despite the rapid growth of the cell therapy market, the design of these cells is still largely a bespoke, craftsman-like process limited by human understanding of biology. “High throughput discovery approaches in cell types such as natural killer cells have lagged behind those in other cell types,” said Alana Welm, Scientific Advisor. “We’re really excited about the therapeutic prospects of exploring the different ways that these cells can be engineered.” Modulus was founded in 2020 by bioengineer Max Darnell, Ph.D. and bioinformatician Bryce Daines, Ph.D., who met as Entrepreneurs-in-Residence at AI2, a research institute created by Microsoft co-founder Paul Allen. The founders set out to invent a platform for systematic and repeatable discovery of next-generation cell therapies to unleash the potential of the immune system against solid tumors. “The AI2 Incubator's mission is to help founders launch AI companies that have the potential to change the world,” said Bryan Hale, Managing Director at the AI2 Incubator. "By harnessing cutting edge AI to seek out life-saving treatments for solid tumors, Modulus has the potential for a truly big impact." While much of the Cell Therapy industry remains focused on problems such as taking existing therapeutic cells and turning them against new targets, Modulus takes a broader approach. Rather than focusing on a single feature, such as targeting, Convergent Design™ enables simultaneous improvement along multiple axes of therapeutic importance converging on optimized cell designs. “Modulus is the only company we’ve seen which is focused on engineering the chassis of these cells.” said Rima Chakrabarti, MD, Principal at KdT Ventures. “By modulating the innate cellular machinery, Modulus can optimize not only for therapeutic efficacy but for improved manufacturability and storage as well, bringing us closer to curative, off-the-shelf immune cell therapies.” Modulus has reengineered the concept of Cell Therapy Discovery by dramatically increasing the number of candidate cells that can be tested simultaneously and using machine learning to interpret the results. As a result, Modulus can learn how entire networks of genes impact a cell’s function, not just one gene at a time. “By combining high-throughput screening with machine learning, to interpret and predict genetic interactions, we get a multiplier on our experimental throughput that dwarfs previous approaches,” said Bryce Daines, Ph.D., co-founder of Modulus. “Repeated over cell types and diseases the result is a flywheel of discovery.” “When combined, these technologies provide a path for discovering the enhancements that cells need to accomplish a complex therapeutic task, like fighting a solid tumor,” said Max Darnell, Ph.D., co-founder of Modulus. “Current cell therapy design is like trying to find your way out of the woods without a GPS. This platform gives us the tools to navigate the cell’s design space systematically and effectively.” For more information about Modulus, please visit https://www.modulustherapeutics.com/ or follow them on Twitter, LinkedIn, Facebook and Instagram. Alana Welm is Senior Director of Basic Science at the Huntsman Comprehensive Cancer Center, Full Professor in the Department of Oncological Sciences at the University of Utah, and an Investigator at the Huntsman Cancer Institute. Welm's laboratory studies breast cancer metastasis. Dr. Raphael Gottardo is Scientific Director, Translational Data Science Integrated Research Center, Professor, and J. Orin Eson Foundation Endowed Chair at Fred Hutch. Dr. Gottardo is a computational biologist and expert in the rapidly evolving field of data science as it is applied to cancer and related diseases. Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Modulus’ Convergent Design™ platform combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and will use its platform to enable partners and develop an internal pipeline of therapeutics. Contact Details Owen Media Forrest Carman +1 206-859-3118 forrestc@owenmedia.com Company Website https://www.modulustherapeutics.com/

July 15, 2021 09:00 AM Pacific Daylight Time

John Steven Joins ThreatModeler's Advisory Board

ThreatModeler Software, Inc.

John Steven is joining the advisory board of ThreatModeler Software, Inc. Mr. Steven has over two decades of software security experience including notable achievements in threat modeling, cloud security, architectural risk analysis, and security testing. In 2015, he founded Codiscope, a spin-off of Cigital which was acquired by Synopsys. He will be working closely with ThreatModeler’s executive team to help shape and guide the company’s planning and go-to-market strategies. “Threat modeling can frustrate organizations because they’re advised to over-rely on singular tactics, such as data-flow diagramming, and because they implement threat modeling as a point-in-time activity. I encourage organizations to treat threat modeling as a capability, incrementally maturing activity throughout their DevOps lifecycle,” said Mr. Steven. “ThreatModeler is uniquely positioned to help teams facilitate threat modeling capabilities throughout their SDL. from secure design, to security test planning, to defect or vulnerability triage and remediation.” Mr. Steven, currently the Chief Technology Officer at Concourse Labs and Founding Principal of Aedify Security LLC, possesses extensive knowledge in managing innovative security firms. His capabilities include identifying and solving cloud risk problems through automated cloud governance, as well as creating efficient threat modeling and security architecture. Mr. Steven is a keynote speaker, co-author of the BSIMM study and has helped several CISOs define and implement their security initiatives. “We’re delighted to welcome John Steven to ThreatModeler. We’re continuously striving to innovate and making one click threat modeling a reality. The experience and insights he brings to our mission will be invaluable,” said Archie Agarwwal, co-founder and CEO of ThreatModeler. About ThreatModeler Software, Inc. ThreatModeler is an automated platform that provides a sustainable, self-service threat modeling practice for applications and infrastructure that evolves as the infrastructure grows. ThreatModeler encourages collaboration through its simple process flow diagram-based functionality. It is easy to use in the creation of threat models which identify, prioritize and mitigate threats, while communicating them broadly. ThreatModeler integrates with JIRA, Jenkins, and Azure Boards and Pipelines, with bidirectional web services API also unifying stakeholders in collaboration. Teams are empowered to code and deliver new products with security built-in as early as the design phase, which is based on global security and compliance standards. Contact Details ThreatModeler Software, Inc Sarah Chan +1 201-266-0510 marketing@threatmodeler.com Company Website https://threatmodeler.com/

July 15, 2021 10:00 AM Eastern Daylight Time

Leaders in built-in antimicrobial technology become a united powerhouse

Microban® International

Microban ® International is proud to announce that it is bringing together its Microban ® and Ultra-Fresh ® brands and technologies under a single umbrella. Following the initial acquisition of Thomson Research Associates in 2016, Microban International will now completely harmonize the two organizations, as these titans unite to operate as a single company under the Microban International name. By consolidating their services and combining over 100 years of collective industry experience, Microban International can better serve its partners all around the world and continue to revolutionize the industry. The Microban brand is widely recognized as the world leader in bespoke antimicrobial and odor-control solutions, delivering Protection That Lives On™ and redefining surface cleanliness. In parallel, the organization’s newly emergent ingredient brand – Ultra-Fresh – delivers improved freshness for a broad spectrum of surfaces. This exciting move will allow the company to harness the trusted Microban brand alongside its Ultra-Fresh offering to create the broadest and most powerful antimicrobial product portfolio in the industry. Microban will continue to develop innovative solutions for both product lines, and further extend its turnkey services and partner support – including technical, regulatory, and legal guidance – to remain a well-rounded and trusted advisor for all. With an ever-growing partner base in 172 countries, advanced facilities around the world, and the addition of Microban laboratories and offices in Canada, Shanghai and Taiwan, partners can look forward to even better coverage, support, and market penetration. Michael Ruby, Vice President of Global Business at Microban International, commented: “Microban is proud to take this step, not only for the company but for its partners. Pushing the boundaries of innovation and building long-standing, meaningful business relationships has always been at the heart of our organization, and this exciting step will allow us to foster, nurture and develop new and existing connections. This is an opportunity for us to move forward; to continue to invest in ground-breaking technologies that benefit end-users, creating the broadest product portfolio in the industry while extending the reach of our valuable turnkey services for all of our partners.” Joe Lyons, President of Microban International, commented: “This is an important moment for the industry, as we consolidate the power of the trusted Microban and Ultra-Fresh brands under one company – Microban International. At Microban International, our brands are truly our strength, and with this move, we will continue to build our brand presence in the consumer, building, textiles, commercial and healthcare sectors, and leverage our capabilities to become a trusted household name and continue as the reigning global market leader.” Click here to learn more about Microban International. About Microban International Part of Barr Brands International (BBI), Microban International is home to the most trusted and well-known global brands in the antimicrobial, odor control, and sanitization / disinfection markets – Microban ® and Ultra-Fresh ®. Our organization has experienced over 100 collective years of growth and has revolutionized the industry. As the global leader, our proactive systems keep products cleaner, and control odors better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products around the world. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina with operations in North America, Europe, and Asia Pacific. For more information, please visit www.microban.com. Editorial contact for further information or follow-up Sarah Khan or Audrey Jestin at kdm communications limited, St Neots, UK Tel. +44 (0) 1480 405333 Fax: +44 (0) 1480 477833 email ideas@kdm-communications.com Contact Details © 2021 kdm communications limited ideas@kdm-communications.com Company Website http://www.microban.com

July 14, 2021 08:01 AM Eastern Daylight Time